{
    "clinical_study": {
        "@rank": "60421", 
        "acronym": "MIR-CABG", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively."
            }, 
            {
                "arm_group_label": "Mupirocin", 
                "arm_group_type": "Experimental", 
                "description": "Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively."
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis is that application of Mupirocin to the nose before and after coronary artery\n      bypass grafting surgery will reduce the incidence of surgical site infections."
        }, 
        "brief_title": "Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Surgical Site Infections", 
        "detailed_description": {
            "textblock": "Mupirocin applied to the nares is effective in eradicating nasal carriage of Staphylococcus\n      species.  Abundant evidence has documented that a majority of gram positive surgical site\n      infections share bacterial phenotypes identical with nasal phage types.  Conflicting\n      literature exists regarding the efficacy of mupirocin in reducing the incidence of surgical\n      site infections.  A randomized prospective double-blind placebo-controlled trial is needed\n      to help settle this question in the setting of coronary artery bypass grafting surgery where\n      surgical site infections carry significant morbidity, cost, and mortality."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults >18 years old undergoing Coronary Artery Bypass Grafting Surgery (CABG) with\n             or without concomitant cardiac valve surgery or other cardiac surgery,\n\n          -  Median sternotomy wound\n\n          -  Capable of informed consent\n\n        Exclusion Criteria:\n\n          -  Allergy to mupirocin or components\n\n          -  Pregnant or lactating females\n\n          -  Emergency surgery\n\n          -  Pre-existing ongoing infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "974", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949935", 
            "org_study_id": "NBHC-MIR004"
        }, 
        "intervention": {
            "arm_group_label": [
                "Control", 
                "Mupirocin"
            ], 
            "intervention_name": "Mupirocin", 
            "intervention_type": "Drug", 
            "other_name": "Bactroban"
        }, 
        "intervention_browse": {
            "mesh_term": "Mupirocin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mupirocin", 
            "Surgical Site Infections", 
            "Coronary Artery Bypass Grafting"
        ], 
        "lastchanged_date": "September 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Saint John", 
                    "country": "Canada", 
                    "state": "New Brunswick", 
                    "zip": "E2L 4L2"
                }, 
                "name": "New Brunswick Heart Centre, Saint John Regional Hospital"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting", 
        "other_outcome": [
            {
                "description": "Subtypes include deep sternal wound, mediastinitis, leg saphenous vein harvest site infections.", 
                "measure": "Incidence of subtypes of surgical site infections.", 
                "safety_issue": "No", 
                "time_frame": "< or = 30 days post operation."
            }, 
            {
                "description": "As diagnosed by sputum, radiographic, and clinical means.", 
                "measure": "Incidence of pneumonia", 
                "safety_issue": "No", 
                "time_frame": "< or = 30 days post operation."
            }
        ], 
        "overall_official": {
            "affiliation": "New Brunswick Heart Centre", 
            "last_name": "Craig D Brown, BSc (Med), MD, FRCSC, FACS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Horizon Health Network Research Ethics Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Surgical site infections (SSI) are classified as superficial, deep, or organ surgical site infections based on CDC definition.", 
            "measure": "Surgical Site Infection", 
            "safety_issue": "No", 
            "time_frame": "<30 days post operation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949935"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Horizon Health Network", 
            "investigator_full_name": "Dr Craig Brown", 
            "investigator_title": "Director of Clinical Trials, New Brunswick Heart Centre", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "< or = 30 days post operation"
            }, 
            {
                "description": "Rashes, rhinorrhea, pruritis, bleeding from nares", 
                "measure": "Serious adverse durg effects", 
                "safety_issue": "Yes", 
                "time_frame": "< or = 30 day post operation"
            }, 
            {
                "description": "Nasal carriage of Staphylococcus aureus assess pre-intervention and post-intervention.", 
                "measure": "S. aureus carrier status", 
                "safety_issue": "No", 
                "time_frame": "< or = 30 day post operation"
            }
        ], 
        "source": "Horizon Health Network", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Horizon Health Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}